BRPI0518209A - agentes de ligação especìficos à angiopoietina-2 - Google Patents

agentes de ligação especìficos à angiopoietina-2

Info

Publication number
BRPI0518209A
BRPI0518209A BRPI0518209-3A BRPI0518209A BRPI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A BR PI0518209 A BRPI0518209 A BR PI0518209A
Authority
BR
Brazil
Prior art keywords
specific binding
binding agents
angiopoietin
antibodies
disclosed
Prior art date
Application number
BRPI0518209-3A
Other languages
English (en)
Inventor
Daniel Jonathon Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of BRPI0518209A publication Critical patent/BRPI0518209A/pt

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

AGENTES DE LIGAçãO ESPECìFICOS à ANGlOPOIETINA-2. São divulgados agentes de ligação especifica, tais como anti-corpos totalmente humanos, que se ligam à angiopoietina-2. Também divulgados são fragmentos de cadeia pesada, fragmentos de cadeia leve e CDRs dos anticorpos, bem como métodos de fabricação e uso dos anticorpos.
BRPI0518209-3A 2004-10-19 2005-10-19 agentes de ligação especìficos à angiopoietina-2 BRPI0518209A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents
PCT/US2005/037911 WO2006045049A1 (en) 2004-10-19 2005-10-19 Angiopoietin-2 specific binding agents

Publications (1)

Publication Number Publication Date
BRPI0518209A true BRPI0518209A (pt) 2008-11-04

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0518209-3A BRPI0518209A (pt) 2004-10-19 2005-10-19 agentes de ligação especìficos à angiopoietina-2

Country Status (10)

Country Link
JP (2) JP2008520188A (pt)
CN (1) CN101495513B (pt)
BR (1) BRPI0518209A (pt)
EA (1) EA011866B1 (pt)
IL (1) IL182279A0 (pt)
MA (1) MA29015B1 (pt)
MX (1) MX2007004247A (pt)
RU (2) RU2404992C2 (pt)
SG (1) SG156668A1 (pt)
ZA (1) ZA200704020B (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
CA2771403C (en) 2009-08-19 2015-02-24 Eisai R&D Management Co. Ltd. Quinoline derivative-containing pharmaceutical composition
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
DK2760471T3 (en) * 2011-09-30 2017-05-08 Dana Farber Cancer Inst Inc THERAPEUTIC PEPTIDES
KR102063028B1 (ko) * 2012-01-23 2020-01-07 리제너론 파아마슈티컬스, 인크. 항-ａｎｇ2 항체를 함유하는 안정화된 제형
WO2014100834A1 (en) * 2012-12-21 2014-06-26 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
EP3187491A4 (en) 2014-08-28 2018-08-01 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
US20180028662A1 (en) 2015-02-25 2018-02-01 Eisai R&D Management Co., Ltd. Method for Suppressing Bitterness of Quinoline Derivative
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
CN108135894B (zh) 2015-08-20 2021-02-19 卫材R&D管理有限公司 肿瘤治疗剂
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
CN110072528B (zh) 2017-02-08 2022-04-26 卫材R&D管理有限公司 治疗肿瘤的药物组合物
WO2018212202A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
US20220204603A1 (en) * 2019-02-25 2022-06-30 Pharmabcine Inc. Anti-ang2 antibody and use thereof
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ514434A (en) * 1999-03-26 2003-11-28 Univ California Modulation of vascular permeability by means of TIE2 receptor activators
EP1179541B1 (en) * 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
PT1292335E (pt) * 2000-06-23 2007-08-13 Bayer Schering Pharma Ag Combinações e composições que interferem na função de receptores vegf/vegf e angiopoietina/ tie e a sua utilização (ii)
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
CA2473970C (en) * 2001-10-12 2013-05-28 Monosolrx Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2

Also Published As

Publication number Publication date
IL182279A0 (en) 2007-07-24
RU2007118670A (ru) 2008-12-27
SG156668A1 (en) 2009-11-26
EA200700876A1 (ru) 2007-10-26
RU2404992C2 (ru) 2010-11-27
ZA200704020B (en) 2008-06-25
CN101495513B (zh) 2014-08-06
CN101495513A (zh) 2009-07-29
RU2010132956A (ru) 2012-02-10
EA011866B1 (ru) 2009-06-30
MX2007004247A (es) 2007-06-12
JP2011207882A (ja) 2011-10-20
JP2008520188A (ja) 2008-06-19
MA29015B1 (fr) 2007-11-01

Similar Documents

Publication Publication Date Title
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
CO6290772A2 (es) Anticuerpos dirigidos a angiopoietina 1 y angiopoietina 2 y usos de los mismos
CY1112993T1 (el) Παραγοντες ειδικης δεσμευσης της αγγειοποιητινης-2 και της αγγειοποιητινης-1
PH12016501691A1 (en) Antibodies to matrix metalloproteinase 9
EA201070888A1 (ru) Антитела и их производные
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
MX2007004247A (es) Agentes de aglutinacion especifica a angiopoyetina-2.
PT1766093E (pt) Anticorpos contra toxinas de clostridium difficile e utilizações dos mesmos
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
EA200970477A1 (ru) Человеческие моноклональные антитела к btla и способы применения
EA200702278A1 (ru) Антитела, специфичные в отношении tgf-бета 1
PH12014501927A1 (en) Antibodies to matrix metalloproteinase 9
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
MX2010006767A (es) Anticuerpos de virus de hepatitis c.
BR112015014751A2 (pt) anticorpos anti-tau humanos
EA201201533A1 (ru) Prlr-специфическое антитело и его применения
MY150400A (en) Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
CL2012000631A1 (es) Anticuerpo capaz de unirse específicamente a un amiloide beta, que comprende los 3 cdrs de cadena liviana (sec nº21/22/23) y los 3 cdrs de cadena pesada (sec nº24/25/26); polinucleótido y línea celular que lo codifican; composición que lo comprende; método de producción y diagnostico; kit; y su uso terapéutico.
BR112012009846B8 (pt) método in vitro e kit para detecção de um anticorpo antifármaco de isotipo ige, e uso de um anticorpo antifármaco de isotipo ige no tratamento de distúrbio mediado por ige
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
SV2006002283A (es) Formulaciones
ATE504602T1 (de) Für humane matriptase spezifische bindungsproteine
MX2007013108A (es) Reactivos que enlazan ccx-ckr2.
GB2419993A (en) Improved search engine optimisation

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2153 DE 10/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.